Adult heights attained by children with hypothalamic/chiasmatic glioma treated with growth hormone

Roy J. Kim, Anna Janss, Dana Shanis, Sarah Homan, Thomas Moshang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hypothalamic/chiasmatic gliomas (H/CG) in children are commonly accompanied by endocrine dysfunction due to mass effects of the tumor itself or as a consequence of tumor therapy, with GH deficiency (GHD) being the most common disorder. We report the height outcomes of GH-treated H/CG patients with GHD. We reviewed the records of 14 GHD patients with H/CG who were treated with human GH. A comparison group of non-GH-treated H/CG patients was also identified. Heights were expressed as SD scores (SDS). For GH-treated patients, the mean initial height was -0.7 ± 0.3 (±SE). Their mean final height was -0.3 ± 0.3. The mean change in height SDS for the GH-treated group was +0.4. The mean initial and final height SDS for the non-GHD patients were 0.6 (SE = 0.4) and 0.0 (SE = 0.4), respectively. The mean change in height SDS was -0.6. The GHD patients had significantly lower initial height SDS compared with the non-GHD patients (P = 0.01) and had a significantly greater change in their height SDS (P = 0.04). GH treatment for H/CG patients restores much of their growth potential and improves adult height to within normal limits.

Original languageEnglish (US)
Pages (from-to)4999-5002
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume89
Issue number10
DOIs
StatePublished - Oct 2004

Fingerprint

Glioma
Growth Hormone
Tumors
Neoplasms
Therapeutics
Growth

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Adult heights attained by children with hypothalamic/chiasmatic glioma treated with growth hormone. / Kim, Roy J.; Janss, Anna; Shanis, Dana; Homan, Sarah; Moshang, Thomas.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 89, No. 10, 10.2004, p. 4999-5002.

Research output: Contribution to journalArticle

Kim, Roy J. ; Janss, Anna ; Shanis, Dana ; Homan, Sarah ; Moshang, Thomas. / Adult heights attained by children with hypothalamic/chiasmatic glioma treated with growth hormone. In: Journal of Clinical Endocrinology and Metabolism. 2004 ; Vol. 89, No. 10. pp. 4999-5002.
@article{ac80d1b5f12d4c739c82ee3deca2e216,
title = "Adult heights attained by children with hypothalamic/chiasmatic glioma treated with growth hormone",
abstract = "Hypothalamic/chiasmatic gliomas (H/CG) in children are commonly accompanied by endocrine dysfunction due to mass effects of the tumor itself or as a consequence of tumor therapy, with GH deficiency (GHD) being the most common disorder. We report the height outcomes of GH-treated H/CG patients with GHD. We reviewed the records of 14 GHD patients with H/CG who were treated with human GH. A comparison group of non-GH-treated H/CG patients was also identified. Heights were expressed as SD scores (SDS). For GH-treated patients, the mean initial height was -0.7 ± 0.3 (±SE). Their mean final height was -0.3 ± 0.3. The mean change in height SDS for the GH-treated group was +0.4. The mean initial and final height SDS for the non-GHD patients were 0.6 (SE = 0.4) and 0.0 (SE = 0.4), respectively. The mean change in height SDS was -0.6. The GHD patients had significantly lower initial height SDS compared with the non-GHD patients (P = 0.01) and had a significantly greater change in their height SDS (P = 0.04). GH treatment for H/CG patients restores much of their growth potential and improves adult height to within normal limits.",
author = "Kim, {Roy J.} and Anna Janss and Dana Shanis and Sarah Homan and Thomas Moshang",
year = "2004",
month = "10",
doi = "10.1210/jc.2004-0484",
language = "English (US)",
volume = "89",
pages = "4999--5002",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Adult heights attained by children with hypothalamic/chiasmatic glioma treated with growth hormone

AU - Kim, Roy J.

AU - Janss, Anna

AU - Shanis, Dana

AU - Homan, Sarah

AU - Moshang, Thomas

PY - 2004/10

Y1 - 2004/10

N2 - Hypothalamic/chiasmatic gliomas (H/CG) in children are commonly accompanied by endocrine dysfunction due to mass effects of the tumor itself or as a consequence of tumor therapy, with GH deficiency (GHD) being the most common disorder. We report the height outcomes of GH-treated H/CG patients with GHD. We reviewed the records of 14 GHD patients with H/CG who were treated with human GH. A comparison group of non-GH-treated H/CG patients was also identified. Heights were expressed as SD scores (SDS). For GH-treated patients, the mean initial height was -0.7 ± 0.3 (±SE). Their mean final height was -0.3 ± 0.3. The mean change in height SDS for the GH-treated group was +0.4. The mean initial and final height SDS for the non-GHD patients were 0.6 (SE = 0.4) and 0.0 (SE = 0.4), respectively. The mean change in height SDS was -0.6. The GHD patients had significantly lower initial height SDS compared with the non-GHD patients (P = 0.01) and had a significantly greater change in their height SDS (P = 0.04). GH treatment for H/CG patients restores much of their growth potential and improves adult height to within normal limits.

AB - Hypothalamic/chiasmatic gliomas (H/CG) in children are commonly accompanied by endocrine dysfunction due to mass effects of the tumor itself or as a consequence of tumor therapy, with GH deficiency (GHD) being the most common disorder. We report the height outcomes of GH-treated H/CG patients with GHD. We reviewed the records of 14 GHD patients with H/CG who were treated with human GH. A comparison group of non-GH-treated H/CG patients was also identified. Heights were expressed as SD scores (SDS). For GH-treated patients, the mean initial height was -0.7 ± 0.3 (±SE). Their mean final height was -0.3 ± 0.3. The mean change in height SDS for the GH-treated group was +0.4. The mean initial and final height SDS for the non-GHD patients were 0.6 (SE = 0.4) and 0.0 (SE = 0.4), respectively. The mean change in height SDS was -0.6. The GHD patients had significantly lower initial height SDS compared with the non-GHD patients (P = 0.01) and had a significantly greater change in their height SDS (P = 0.04). GH treatment for H/CG patients restores much of their growth potential and improves adult height to within normal limits.

UR - http://www.scopus.com/inward/record.url?scp=6344235095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6344235095&partnerID=8YFLogxK

U2 - 10.1210/jc.2004-0484

DO - 10.1210/jc.2004-0484

M3 - Article

VL - 89

SP - 4999

EP - 5002

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 10

ER -